207 related articles for article (PubMed ID: 35535227)
21. Mutations of the
Liu R; Li Y; Chen W; Cong J; Zhang Z; Ma L; Chu L; Xiao H; Zhang Y; Liu Y; Xu Y; Yu Q; Yang X; Sun C
Oncol Lett; 2020 Oct; 20(4):50. PubMed ID: 32802170
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for contralateral central lymph node metastasis in unilateral cN0 papillary thyroid carcinoma: A meta-analysis.
Yan B; Hou Y; Chen D; He J; Jiang Y
Int J Surg; 2018 Nov; 59():90-98. PubMed ID: 30342280
[TBL] [Abstract][Full Text] [Related]
23. Coexistence of
Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646
[No Abstract] [Full Text] [Related]
24. Advances in Detecting Low Prevalence Somatic
da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
[TBL] [Abstract][Full Text] [Related]
25. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
[TBL] [Abstract][Full Text] [Related]
26. Suspicious ultrasound and clinicopathological features of papillary thyroid carcinoma predict the status of TERT promoter.
Shi H; Guo LH; Zhang YF; Fu HJ; Zheng JY; Wang HX; Zhao CK; Xu HX
Endocrine; 2020 May; 68(2):349-357. PubMed ID: 32026251
[TBL] [Abstract][Full Text] [Related]
27. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
28. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
29. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
[TBL] [Abstract][Full Text] [Related]
30. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
31. Co-existence of
Ren H; Shen Y; Hu D; He W; Zhou J; Cao Y; Mao Y; Dou Y; Xiong W; Xiao Q; Zhang Y; Su X
Cancer Manag Res; 2018; 10():1005-1013. PubMed ID: 29760568
[TBL] [Abstract][Full Text] [Related]
32. Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients.
Yang H; Park H; Ryu HJ; Heo J; Kim JS; Oh YL; Choe JH; Kim JH; Kim JS; Jang HW; Kim TH; Kim SW; Chung JH
Endocrinol Metab (Seoul); 2022 Aug; 37(4):652-663. PubMed ID: 35864728
[TBL] [Abstract][Full Text] [Related]
33. Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma.
Kim HJ; Sohn SY; Jang HW; Kim SW; Chung JH
World J Surg; 2013 Feb; 37(2):376-84. PubMed ID: 23135422
[TBL] [Abstract][Full Text] [Related]
34. Frequent BRAF
Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
[TBL] [Abstract][Full Text] [Related]
35. The Coexistence of Genetic Mutations in Thyroid Carcinoma Predicts Histopathological Factors Associated With a Poor Prognosis: A Systematic Review and Network Meta-Analysis.
Zhao L; Wang L; Jia X; Hu X; Pang P; Zhao S; Wang Y; Wang J; Zhang Y; Lyu Z
Front Oncol; 2020; 10():540238. PubMed ID: 33240806
[TBL] [Abstract][Full Text] [Related]
36. Risk Factors for Central Lymph Node Metastasis in CN0 Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
Sun W; Lan X; Zhang H; Dong W; Wang Z; He L; Zhang T; Liu S
PLoS One; 2015; 10(10):e0139021. PubMed ID: 26431346
[TBL] [Abstract][Full Text] [Related]
37. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Xing M; Liu R; Liu X; Murugan AK; Zhu G; Zeiger MA; Pai S; Bishop J
J Clin Oncol; 2014 Sep; 32(25):2718-26. PubMed ID: 25024077
[TBL] [Abstract][Full Text] [Related]
38. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
[TBL] [Abstract][Full Text] [Related]
39. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer.
Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897
[TBL] [Abstract][Full Text] [Related]
40. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.
Sun J; Zhang J; Lu J; Gao J; Ren X; Teng L; Duan H; Lin Y; Li X; Zhang B; Liang Z
PLoS One; 2016; 11(4):e0153319. PubMed ID: 27064992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
